These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8080210)

  • 1. Immunogenicity of two types of Shigella flexneri 2a O-specific polysaccharide-tetanus toxoid conjugates.
    Polotsky VY; Schneerson R; Bryla D; Robbins JB
    Ann N Y Acad Sci; 1994 Aug; 730():359-60. PubMed ID: 8080210
    [No Abstract]   [Full Text] [Related]  

  • 2. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids.
    Taylor DN; Trofa AC; Sadoff J; Chu C; Bryla D; Shiloach J; Cohen D; Ashkenazi S; Lerman Y; Egan W
    Infect Immun; 1993 Sep; 61(9):3678-87. PubMed ID: 8359890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid.
    Chu CY; Liu BK; Watson D; Szu SS; Bryla D; Shiloach J; Schneerson R; Robbins JB
    Infect Immun; 1991 Dec; 59(12):4450-8. PubMed ID: 1937803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of two types of meningococcal group C polysaccharide conjugates using tetanus toxoid as carrier protein.
    Beuvery EC; Roy R; Kanhai V; Jennings HJ
    Dev Biol Stand; 1986; 65():197-204. PubMed ID: 3104115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of conjugates composed of lipopolysaccharide from Shigella flexneri type 2a detoxified by two methods and bound to tetanus toxoid.
    Polotsky VY; Robbins JB; Bryla D; Schneerson R
    Infect Immun; 1994 Jan; 62(1):210-4. PubMed ID: 8262629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of tetanus toxoid conjugates of anti-idiotypes that mimic Pseudomonas aeruginosa surface polysaccharides.
    Schreiber JR; Dahlhauser P
    Infect Immun; 1994 Jan; 62(1):308-12. PubMed ID: 8262644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines.
    Beuvery EC; Miedema F; van Delft R; Haverkamp J
    Infect Immun; 1983 Apr; 40(1):39-45. PubMed ID: 6187693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection.
    Phalipon A; Tanguy M; Grandjean C; Guerreiro C; Bélot F; Cohen D; Sansonetti PJ; Mulard LA
    J Immunol; 2009 Feb; 182(4):2241-7. PubMed ID: 19201878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes.
    Gupta RK; Egan W; Bryla DA; Robbins JB; Szu SC
    Infect Immun; 1995 Aug; 63(8):2805-10. PubMed ID: 7542631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.
    Ashkenazi S; Passwell JH; Harlev E; Miron D; Dagan R; Farzan N; Ramon R; Majadly F; Bryla DA; Karpas AB; Robbins JB; Schneerson R
    J Infect Dis; 1999 Jun; 179(6):1565-8. PubMed ID: 10228084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice.
    Pavliakova D; Chu C; Bystricky S; Tolson NW; Shiloach J; Kaufman JB; Bryla DA; Robbins JB; Schneerson R
    Infect Immun; 1999 Oct; 67(10):5526-9. PubMed ID: 10496944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates.
    Jennings HJ; Lugowski C
    J Immunol; 1981 Sep; 127(3):1011-8. PubMed ID: 6790606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycoconjugate vaccines and immune interference: A review.
    Dagan R; Poolman J; Siegrist CA
    Vaccine; 2010 Aug; 28(34):5513-23. PubMed ID: 20600514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide.
    Gudlavalleti SK; Lee CH; Norris SE; Paul-Satyaseela M; Vann WF; Frasch CE
    Vaccine; 2007 Nov; 25(46):7972-80. PubMed ID: 17936445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Shigella dysenteriae serotype 1 O-antigenic polysaccharide by Shigella flexneri aroD vaccine candidates and different S. flexneri serotypes.
    Fält IC; Schweda EK; Klee S; Singh M; Floderus E; Timmis KN; Lindberg AA
    J Bacteriol; 1995 Sep; 177(18):5310-5. PubMed ID: 7545156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physicochemical and immunological characterization of meningococcal group A polysaccharide-tetanus toxoid conjugates prepared by two methods.
    Beuvery EC; vd Kaaden A; Kanhai V; Leussink AB
    Vaccine; 1983 Dec; 1(1):31-6. PubMed ID: 6442499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation, antigenicity, and immunogenicity of synthetic ribosylribitol phosphate oligomer-protein conjugates and their potential use for vaccination against Haemophilus influenzae type b disease.
    Evenberg D; Hoogerhout P; van Boeckel CA; Rijkers GT; Beuvery EC; van Boom JH; Poolman JT
    J Infect Dis; 1992 Jun; 165 Suppl 1():S152-5. PubMed ID: 1588151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
    Baker CJ; Paoletti LC; Wessels MR; Guttormsen HK; Rench MA; Hickman ME; Kasper DL
    J Infect Dis; 1999 Jan; 179(1):142-50. PubMed ID: 9841833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a.
    Dharmasena MN; Osorio M; Takeda K; Stibitz S; Kopecko DJ
    Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29046309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
    Wessels MR; Paoletti LC; Kasper DL; DiFabio JL; Michon F; Holme K; Jennings HJ
    J Clin Invest; 1990 Nov; 86(5):1428-33. PubMed ID: 2243123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.